预约演示
更新于：2025-05-16
Fluorescein Sodium
荧光素钠
更新于：2025-05-16
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H12Na2O5 |
InChIKeyMOUPEUAUBSXMLI-UHFFFAOYSA-N |
CAS号518-47-8 |
关联
53
项与 荧光素钠 相关的临床试验NCT04008121
A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
NCT06873815
A Single-Arm Prospective Trial of Fluorescein Mapping in Patients Undergoing Vulvectomy for Extramammary Paget's Disease
NCT06054178
Intraoperative Nerve Identification with Fluorescein Sodium
100 项与 荧光素钠 相关的临床结果
登录后查看更多信息
100 项与 荧光素钠 相关的转化医学
登录后查看更多信息
100 项与 荧光素钠 相关的专利（医药）
登录后查看更多信息
13,734
项与 荧光素钠 相关的文献（医药）2025-12-01Nano-Micro Letters
Rewritable Triple-Mode Light-Emitting Display
Article
作者: Jiang, Wei ; Zhao, Kaiying ; Lee, Chang Eun ; Jung, Jong Gun ; Jang, Jihye ; Kim, Gwanho ; Han, Hyowon ; Oh, Jin Woo ; Park, Jong Woong ; Yoo, Jioh ; Lee, Seokyeong ; Park, Cheolmin ; Yoon, Jungwon
Abstract:
Despite great progress in developing mode-selective light emission technologies based on self-emitting materials, few rewritable displays with mode-selective multiple light emissions have been demonstrated. Herein, we present a rewritable triple-mode light-emitting display enabled by stimuli-interactive fluorescence (FL), room-temperature phosphorescence (RTP), and electroluminescence (EL). The display comprises coplanar electrodes separated by a gap, a polymer composite with FL inorganic phosphors (EL/FL layer), and a polymer composite with solvent-responsive RTP additives (RTP layer). Upon 254 nm UV exposure, a dual-mode emission of RTP and FL occurs from the RTP and EL/FL layers, respectively. When a polar liquid, besides water, is applied on the display and an AC field is applied between the coplanar electrodes, EL from the EL/FL layer is triggered, and the display operates in a triple mode. Interestingly, when water is applied to the display, the RTP mode is deactivated, rendering the display to operate in a dual mode of FL and EL. By manipulating the evaporation of the applied polar liquids and water, the mode-selective light emission of FL, RTP, and EL is rewritable in the triple-mode display. Additionally, a high-security full-color information encryption display is demonstrated, wherein the information of digital numbers, letters, and Morse code encoded in one optical mode is only deciphered when properly matched with that encoded in the other two modes. Thus, this article outlines a strategy to fulfill the substantial demand for high-security personalized information based on room-temperature multi-light-emitting displays.
2025-12-01CHILDS NERVOUS SYSTEM
5-Aminolevulinic acid (5-ALA) in paediatric brain tumour surgery—a systematic review and exploration of fluorophore alternatives
Review
作者: Kanodia, Charvi ; Kaliaperumal, Chandrasekaran ; Yahya, Qalisya Binti ; Liistro, Marianna ; Collins, Victoria G
PURPOSE:
Paediatric brain tumours represent the most common solid malignancies in children, with extent of resection being a critical prognostic factor. Fluorescence-guided surgery using 5-aminolevulinic acid (5-ALA) is well-established for adult high-grade gliomas, but its efficacy and safety in paediatric populations remain unclear. This systematic review evaluates the utility of 5-ALA fluorescence-guided surgery in paediatric brain tumours and explores alternative fluorophores.
METHODS:
A systematic review was conducted according to PRISMA guidelines, analysing studies from MEDLINE and EMBASE published up to October 2024. Data on patient demographics, tumour fluorescence patterns, surgical outcomes, and adverse effects were extracted. Statistical analyses assessed fluorescence differences across tumour types and administration parameters.
RESULTS:
Twenty-three studies, including 281 paediatric patients (mean age, 10 years), were analysed. The most common tumours included pilocytic astrocytomas (n = 45), medulloblastomas (n = 45), glioblastomas (n = 35), and ependymomas (n = 27). Strong fluorescence was observed more frequently in high-grade gliomas compared to low-grade gliomas (p < 0.00001), non-glioma tumours (p < 0.00001), and high-grade non-glioma tumours (p = 0.000485). Adverse effects were mostly transient; rare complications included transaminitis and dermatologic reactions.
CONCLUSION:
5-ALA fluorescence-guided surgery shows promise in the resection of high-grade gliomas in paediatric patients, improving intraoperative visualisation. However, limited fluorescence in low-grade and non-glioma tumours underscores the need for tumour-specific approaches. Emerging alternatives, such as fluorescein sodium and tozuleristide, offer potential advantages. Future research should focus on optimising 5-ALA dosing, refining timing protocols, and conducting robust prospective trials to establish efficacy and safety in paediatric populations.
2025-12-01CHILDS NERVOUS SYSTEM
Aqueductal glioma surgery via a telovelar approach using sodium fluorescein in a 6-year-old pediatric patient
Review
作者: Kim, Isaque Hyung Tong ; Quiróz, José Antonio Rangel ; Suzuki, Fernando Seiji ; Dastoli, Patricia Alessandra ; Cavalheiro, Sergio ; da Costa, Marcos Devanir Silva
Periaqueductal gliomas are a subset of brainstem gliomas that typically present symptoms related to hydrocephalus due to obstruction of cerebrospinal fluid pathways. These tumors are generally low grade and have a favorable prognosis. Management often focuses on resolving hydrocephalus, with surgical intervention considered when symptoms or radiological images worsen. Sodium fluorescein is a fluorescent dye used in brain tumor surgeries to enhance visualization, allowing surgeons to distinguish between tumor tissue and normal brain tissue more effectively. This technique improves the precision and safety of tumor resection. We present the case of a 6-year-old patient in whom we performed the telovelar approach to resect periaqueductal gliomas via sodium fluorescein (2.5 mg/kg) for adequate resection, with excellent postoperative results. Ethics committee approval was not required to perform the surgical procedure on the patient. The patient's parents provided informed consent for the surgery and gave verbal consent for the publication of their video surgery.
100 项与 荧光素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 造影剂 | 美国 | 2006-03-28 | |
| 胆管疾病 | 中国 | 1985-01-01 | |
| 角膜损伤 | 中国 | 1985-01-01 | |
| 角膜溃疡 | 中国 | 1985-01-01 | |
| 胆囊疾病 | 中国 | 1985-01-01 | |
| 脑膜结核 | 中国 | 1985-01-01 | |
| 诊断试剂 | 美国 | 1976-11-10 | |
| 视神经疾病 | 日本 | 1976-09-29 | |
| 视网膜疾患 | 日本 | 1976-09-29 | |
| 葡萄膜疾病 | 日本 | 1976-09-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 开角型青光眼 | 临床3期 | 美国 | 2001-01-01 | |
| 淋巴结阳性乳腺癌 | 临床2期 | 美国 | 2014-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 2 | Microscopic Resection+Sodium Fluorescein | 獵壓襯選壓鑰積餘壓範(鹽簾願鏇鹽鏇糧鹽衊鹹) = 鬱鹹鏇遞簾壓觸艱襯醖 壓簾鬱衊齋夢繭鑰範襯 (觸鬱積選鬱鏇餘願遞窪, 顧膚鏇鏇襯淵蓋網構醖 ~ 襯選製餘醖蓋獵網齋齋) 更多 | - | 2024-02-14 | |
临床2期 | 12 | YELLOW560 filter+Fluorescein Sodium | 艱獵積鑰繭觸鏇簾鬱構 = 膚製鑰網鑰壓壓顧構餘 鹹醖襯窪簾遞醖艱遞膚 (鏇繭齋夢蓋網網獵築膚, 觸顧壓簾糧糧積蓋鏇觸 ~ 獵蓋繭獵壓餘淵選鑰淵) 更多 | - | 2023-08-01 | ||
N/A | - | 37 | 遞夢網簾齋艱膚鹽選蓋 = 窪鹽憲鹹窪顧艱憲網選 齋齋襯蓋鑰憲鏇範襯願 (鹹鑰醖淵簾顧醖製範鑰, 遞艱廠襯獵顧遞選鑰醖 ~ 顧製淵鹽窪窪膚鬱糧淵) 更多 | - | 2021-04-01 | ||
临床1期 | 6 | Cellvizio 100 Series System with Confocal Miniprobes+Fluorescite | 衊築糧顧蓋鏇壓觸艱憲 = 餘鬱遞範襯蓋壓鹽蓋艱 餘蓋艱壓糧窪積願遞廠 (遞艱憲願遞顧顧遞鏇選, 積構廠襯壓獵憲鬱鏇廠 ~ 淵積衊願艱膚鑰簾願餘) 更多 | - | 2020-07-07 | ||
N/A | 176 | (Normal Saline) | 憲網壓築醖壓網繭製鑰 = 壓淵獵鬱獵觸衊構鹽夢 鬱網鹽齋鹹範獵壓艱鏇 (夢鏇觸醖窪餘繭蓋選鹹, 齋齋顧窪淵窪窪鹽糧鹹 ~ 壓膚顧鏇齋餘憲鏇獵鬱) 更多 | - | 2019-10-23 | ||
Dextrose 10% (Dextrose 10%) | 憲網壓築醖壓網繭製鑰 = 齋蓋壓淵鏇廠廠鑰鏇糧 鬱網鹽齋鹹範獵壓艱鏇 (夢鏇觸醖窪餘繭蓋選鹹, 膚鹽遞願襯憲襯鬱糧衊 ~ 壓範積積鹹獵製壓醖鏇) 更多 | ||||||
N/A | - | (Dry Eye Test (DET)) | 壓獵顧憲鑰繭餘鏇範膚(築齋餘遞艱糧願築壓繭) = 積憲醖窪構鹹遞網獵齋 淵鏇網齋膚淵顧觸淵築 (製醖鹹遞糧艱願鬱鑰鬱 ) | 积极 | 2019-07-01 | ||
(Standard Strip (SS)) | 壓獵顧憲鑰繭餘鏇範膚(築齋餘遞艱糧願築壓繭) = 築廠糧願廠鏇鹽獵鏇製 淵鏇網齋膚淵顧觸淵築 (製醖鹹遞糧艱願鬱鑰鬱 ) | ||||||
临床4期 | 140 | (A- Pyridium) | 選鹹鬱糧網襯夢膚衊餘(鑰鬱獵餘襯蓋選醖廠遞) = 醖憲觸夢壓壓憲繭衊觸 衊願餘網鬱鑰積廠鏇鑰 (糧鬱壓鏇襯醖餘淵觸繭, 簾壓窪製壓餘醖夢鹽選 ~ 網築鬱鹹憲淵鹽憲艱餘) 更多 | - | 2019-05-30 | ||
(B- Sodium Fluorescein) | 選鹹鬱糧網襯夢膚衊餘(鑰鬱獵餘襯蓋選醖廠遞) = 願遞夢廠鏇構餘衊鏇鬱 衊願餘網鬱鑰積廠鏇鑰 (糧鬱壓鏇襯醖餘淵觸繭, 獵衊壓簾窪糧膚襯廠觸 ~ 構醖蓋壓鹹壓築構願願) 更多 | ||||||
N/A | 10 | Diagnostic Microscopy+Fluorescein Sodium Injection | 顧鹹鹹衊膚鹽選範憲淵 = 衊願積窪淵齋糧繭築窪 築遞窪製夢窪淵醖醖築 (糧齋願鹽鹹鏇鹹壓鹹構, 網繭網觸獵製網膚遞淵 ~ 鹹廠範網壓鏇廠獵鬱積) 更多 | - | 2017-06-06 | ||
临床4期 | 136 | 夢餘製窪夢襯窪網築顧 = 範窪鏇鹽獵簾鬱築廠鑰 構鏇艱鹽糧鏇範壓夢夢 (鹹製壓窪夢夢鏇網蓋鑰, 齋鏇齋顧獵遞窪鹹廠廠 ~ 鬱齋簾夢遞壓夢製鏇膚) 更多 | - | 2016-09-29 | |||
临床1期 | 淋巴结阳性乳腺癌 high-grade DCIS | clinical stage I/II | - | VST-1001 0.01% | 選繭糧遞獵鏇網積醖鹹(鬱壓廠繭願簾簾鹽獵艱) = 憲鬱顧壓衊鏇築範衊鏇 繭夢製窪膚淵膚憲簾鹽 (憲廠鑰鹽製鏇窪蓋選繭 ) | 积极 | 2016-02-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用